Advertisement
YOU ARE HERE: LAT HomeCollectionsInamed Corp
IN THE NEWS

Inamed Corp

FEATURED ARTICLES
BUSINESS
January 10, 2006
* Allergan Inc. of Irvine, which is buying Santa Barbara-based Inamed Corp. for $3.42 billion, said it was extending the expiration date of its exchange offer for all outstanding shares of Inamed stock. The offer now will expire at 5 p.m. Eastern time Jan. 24, Allergan said.
ARTICLES BY DATE
BUSINESS
February 7, 2006
* A federal court in New Jersey awarded $112 million in damages to Texas Instruments Inc. of Dallas in its patent infringement case against Conexant Systems Inc. of Newport Beach. A Conexant unit infringed three patents related to digital subscriber line technology, the court found. * Virgin America Inc. said it named as its chairman Don Carty, the former chairman and chief executive of AMR Corp. * Allergan Inc. extended the deadline for investors to trade in their Inamed Corp.
Advertisement
BUSINESS
August 16, 2002 | Bloomberg News
Inamed Corp., a medical device company that disclosed an accounting review this week, said it has named Robert S. Vaters its chief financial officer. Vaters, 42, replaces interim CFO Declan Daley, who will remain controller and principal accounting officer, the company said. Vaters was chief operating officer at telecommunications company Arbinet Holdings Inc. and is a former CFO of Premiere Technologies, Inamed said.
BUSINESS
January 24, 2006 | From Reuters
Botox maker Allergan Inc. said it was extending its $3.2-billion offer to buy breast implant maker Inamed Corp. because it had yet to get antitrust clearance from regulators. The offer is now set to expire at 8 p.m. on Feb. 7; it had been set to expire today. Irvine-based Allergan and Santa Barbara-based Inamed said they were working with the Federal Trade Commission to complete the sale of Inamed's license for Reloxin, a botulism toxin product.
BUSINESS
August 13, 2002 | Bloomberg News
Inamed Corp., the maker of a surgical device to treat obesity, said it's reviewing the way it accounted for debt, taxes and warranties for breast implants and may have costs of as much as $10.5 million. The announcement, made after the markets closed, sent shares of the Santa Barbara-based company down as much as $4.19, or 23%, to $14.22 in after-hours trading. They had closed up 11 cents at $18.41 on Nasdaq.
BUSINESS
May 23, 2003 | From Bloomberg News
Inamed Corp.'s 2000 agreement with a Johnson & Johnson unit to resolve a patent and royalties dispute over an obesity treatment was a valid contract, a federal appeals court concluded. The appellate court decided that a federal judge in Los Angeles had erred in concluding that the agreement with Dr. Lubomyr Kuzmak and Ethicon Endo-Surgery was not a binding contract, Inamed Vice President Peter Nicholson said. Ethicon is a Johnson & Johnson unit.
BUSINESS
January 8, 2004 | From Bloomberg News
Inamed Corp. of Santa Barbara, a maker of medical devices seeking to sell the first silicone-gel breast implant in the U.S. in 11 years, said it received a "not approvable" letter from the Food and Drug Administration. The letter outlines what information Inamed must provide to the FDA on silicone-gel breast implants, the company said.
BUSINESS
April 24, 2004 | From Bloomberg News
Inamed Corp. and its partner Genzyme Corp. won Food and Drug Administration approval of the Hylaform gel to treat wrinkles around the eyes and mouth. Inamed, which already sells other wrinkle fillers, will compete with Medicis Pharmaceutical Corp.'s Restylane, which won U.S. approval in December. Shares of Santa Barbara-based Inamed rose $2 to $55.50 on Nasdaq. Genzyme shares fell 64 cents to $46.46, also on Nasdaq.
BUSINESS
December 16, 2005 | From Reuters
Inamed Corp. said its board had unanimously approved Botox maker Allergan Inc.'s $3.2-billion offer in a deal that would allow Allergan to expand its wrinkle-treatment product line. Inamed, which also makes breast implants, said it hadn't signed the agreement, which wouldn't be finalized until Irvine-based Allergan said it was satisfied with its investigation of Inamed's wrinkle smoother Juvederm. Santa Barbara-based Inamed this week agreed to pay a $90-million breakup fee to end its $2.
BUSINESS
December 3, 2004 | Denise Gellene
Inamed Corp. of Santa Barbara won Food and Drug Administration approval for Captique, an injectable gel to combat facial wrinkles. The product uses hyaluronic acid, a substance that naturally occurs in skin, to plump out wrinkles. Inamed's first-generation hyaluronic gel, Hylaform, was made from ground rooster combs. Captique does not contain animal products. The gels compete with Medicis Pharmaceutical Corp.'s Restylane and are alternatives to collagen, Inamed's mainstay wrinkle treatment.
BUSINESS
December 21, 2005 | From Bloomberg News
Irvine-based Allergan Inc., maker of the Botox anti-wrinkle treatment, agreed to buy Santa Barbara-based Inamed Corp., which last week ended an agreement to be acquired by Medicis Pharmaceutical Corp., for $3.42 billion in cash and stock. Inamed shareholders would get either $84 in cash or 0.85 Allergan share per Inamed share, or an equivalent combination of stock and cash. Forty-five percent of the deal would be in cash and 55% in stock. The deal is expected to close in January.
BUSINESS
December 16, 2005 | From Reuters
Inamed Corp. said its board had unanimously approved Botox maker Allergan Inc.'s $3.2-billion offer in a deal that would allow Allergan to expand its wrinkle-treatment product line. Inamed, which also makes breast implants, said it hadn't signed the agreement, which wouldn't be finalized until Irvine-based Allergan said it was satisfied with its investigation of Inamed's wrinkle smoother Juvederm. Santa Barbara-based Inamed this week agreed to pay a $90-million breakup fee to end its $2.
BUSINESS
November 17, 2005 | From Associated Press
Cosmetic surgery product maker Inamed Corp. said its board of directors had instructed management to evaluate a proposed $3.2-billion cash-and-stock takeover bid from Botox maker Allergan Inc. that could trump a competing offer. Santa Barbara-based Inamed, which makes breast implants and other cosmetic treatment products, had been in talks to be acquired by Medicis Pharmaceutical Corp. for $2.8 billion in cash and stock. Inamed shares rose $1.51 to $82.79. Medicis shares rose 9 cents to $26.
BUSINESS
November 10, 2005 | From Bloomberg News
Silicone breast-implant maker Inamed Corp. said Wednesday that Securities and Exchange Commission staff would recommend closing a formal inquiry into the company. The company was told in February that the commission had begun a probe probably related to disclosures about one style of silicone breast implant. The company said it cooperated. That model of implant accounted for less than 1% of Inamed's 2004 sales, the filing said.
BUSINESS
March 17, 2005 | From Reuters
Inamed Corp. said Wednesday that U.S. regulators had started a formal investigation into its disclosures about one style of its silicone gel-filled breast implant products. The Santa Barbara-based company said in its annual report that it received notification of the Securities and Exchange Commission investigation on Feb. 24 and that it intended to cooperate fully.
BUSINESS
December 3, 2004 | Denise Gellene
Inamed Corp. of Santa Barbara won Food and Drug Administration approval for Captique, an injectable gel to combat facial wrinkles. The product uses hyaluronic acid, a substance that naturally occurs in skin, to plump out wrinkles. Inamed's first-generation hyaluronic gel, Hylaform, was made from ground rooster combs. Captique does not contain animal products. The gels compete with Medicis Pharmaceutical Corp.'s Restylane and are alternatives to collagen, Inamed's mainstay wrinkle treatment.
BUSINESS
April 24, 2004 | From Bloomberg News
Inamed Corp. and its partner Genzyme Corp. won Food and Drug Administration approval of the Hylaform gel to treat wrinkles around the eyes and mouth. Inamed, which already sells other wrinkle fillers, will compete with Medicis Pharmaceutical Corp.'s Restylane, which won U.S. approval in December. Shares of Santa Barbara-based Inamed rose $2 to $55.50 on Nasdaq. Genzyme shares fell 64 cents to $46.46, also on Nasdaq.
Los Angeles Times Articles
|